Stemline Therapeutics (STML) Sees IPO Price of $10 - $12/Share
Tweet
Share
E-mail
Get Alerts STML Hot Sheet
Join SI Premium – FREE
Stemline Therapeutics (Nasdaq: STML) filed an amended registration with the U.S. SEC for an Initial Public Offering of its Common Stock. The company plans to sell 1,819,000 shares and sees an offering price of $10 to $12 per share. The company plans to list on the Nasdaq under the symbol, "STML."
The offering is being made through Aegis Capital Corp.
Stemline is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing proprietary therapeutics that target both cancer stem cells, or CSCs, and tumor bulk.
The offering is being made through Aegis Capital Corp.
Stemline is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing proprietary therapeutics that target both cancer stem cells, or CSCs, and tumor bulk.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Silence Therapeutics closes $201M public offering of ADSs
- Daré Bioscience prices $6M direct offering at $1.37 per share
- Avnet (AVT) files mixed shelf
Create E-mail Alert Related Categories
IPOsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
